Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

BMC Cancer

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Progressive Disease

Show all topics

DOI

10.1186/1471-2407-11-1

License

CC-BY

Other Formats

PDF